Cellular Pharmacology of Fludarabine Triphosphate in Chronic Lymphocytic Leukemia Cells During Fludarabine Therapy

References

• Brockman R. W., Schabel F. M., Jr., Montgomery J. A. Biologic activity of 9-β-D-arabinofuranosyl-2-nuor-oadenine, a metabolically stable analog of 9-β-D-arabinofur-anosyl-adenine. Biochem. Pharmacol. 1977; 26: 2193–2196
   PubMed Web of Science ®Google Scholar
• Brockman R. W., Cheng Y. C., Schabel F. M., Jr., Montgomery J. A. Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res. 1980; 40: 3610–3615
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Rottmann R., Wormann B., Thiel A., Essink M., Ottensmeier C., Freund M., Buchner T., van de Loo J. Treatment of advanced chronic lymphocytic leukemia by fludarabine: results of a clinical phase-II study. Ann. Hematol. 1991; 63: 1–4
   PubMed Web of Science ®Google Scholar
• Puccio C. A., Mittleman A., Lichtman S. M., Silver R. T., Budman D. R., Ahmed T., Feldman E. J., Coleman M., Arnold P. M., Arlin Z. A., Chun H. G. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J. Clin. Oncol 1991; 9: 1562–1569
   PubMed Web of Science ®Google Scholar
• Grever M. R., Leiby J., Kraut E., Metz E., Neidhart J., Balcerzak S., Malspeis L. A comprehensive phase I and II clinical investigation of fludarabine phosphate. Sent. Oncol. 1990; 5(Suppl. 8)39–48
   Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., Redman J., Roller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., Roller C., Talpaz M., Sachner J., Childs C. G., Freireich E. J., McCredie K. B. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Hutton J. J., Von Hoft D. D., Kuhn J., Phillips J., Hersh M., Clark G. Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984; 44: 4183–4186
   PubMed Web of Science ®Google Scholar
• Hersh M. R., Kuhn J. G., Phillips J. L., Clarke G., Ludden T. M., Von Hoff D. D. Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemolher. Pharmacol. 1986; 17: 277–280
   PubMed Web of Science ®Google Scholar
• Danhauser L., Plunkett W., Keating M., Cabanillas F. 9-β-D-arabinofuranosyl-2-fluoroadenine 5'-mono-phosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemolher. Pharmacol. 1986; 18: 145–152
   PubMed Web of Science ®Google Scholar
• Malspeis L., Grever M. R., Staubus A. E., Young D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofur-anosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate. Sem. Oncol. 1990; 5(Suppl)18–32
   Google Scholar
• Dow L. W., Bell D. E., Poulakos L., Fridland A. Differences in metabolism and cytotoxicity between 9-β-D-arabinofuranosyladenine and 9-β-D-arabinofuranosyl-2-fluor-oadenine in human leukemic lymphoblasts. Cancer Res. 1980; 40: 1405–1410
   PubMed Web of Science ®Google Scholar
• Plunkett W., Iacoboni S., Estey E., Danhauser L., Liliemark J. O., Keating M. J. Pharmacologically directed ara-C therapy for refractory leukemia. Semin. Oncol. 1985; 12: (Suppl), 20–30
   Web of Science ®Google Scholar
• Kantarjian H. M., Estey E. H., Plunkett W., Keating M. J., Walters R. S., Iacoboni S., McCredie K. B., Freireich E. J. Phase I II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am. J. Med 1986; 81: 387–394
   PubMed Web of Science ®Google Scholar
• Estey E., Plunkett W., Dixon D. O., Keating M., McCredie K., Freirech E. J. Variables predicing response to high dose cytosine arabinoside therapy with refractory acute leukemia. Leukemia 1987; 1: 580–583
   PubMed Web of Science ®Google Scholar
• Estey E. H., Keating M. J., McCredie K. B., Freireich E. J., Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 1990; 4: 95–99
   PubMed Web of Science ®Google Scholar
• Plunkett W., Liliemark J. O., Adams T. M., Nowak B., Estey E., Kantarjian H., Keating M. J. Saturation of 1-β-D-arabinosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose l-β-D-arabinosylcytosine therapy. Cancer Res. 1987; 47: 3005–3011
   PubMed Web of Science ®Google Scholar
• Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Plunkett W., Hug V., Keating M. J., Chubb S. Quantitation of l-β-D-arabinofuranosylcytosine 5'-triphos-phate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res. 1980; 40: 588–591
   PubMed Web of Science ®Google Scholar
• Kemena A., Keating M. J., Plunkett W. Plasma and cellular bioavailability of oral fludarabine. Blood 1991; 78: 52a
   Google Scholar
• Plunkett W., Huang P., Gandhi V. Metabolism and action of fludarabine phosphate. Sem. Oncol. 1990; 17(Suppl 8)3–17
   PubMed Web of Science ®Google Scholar
• Huang P., Plunkett W. Cell cycle-dependent apoptosis induced by nucleoside analogues. [Abstract] Proc. Am. Assoc. Cancer Res. 1992; 33: 151
   Google Scholar
• Leiby J. M., Snider K. M., Kraut E. H., Metz E. N., Malspeis L., Grever M. R. Phase II trial of 9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: perspective comparison of response with deoxycytidine kinase activity. Cancer Res. 1987; 47: 2719–2722
   PubMed Web of Science ®Google Scholar
• White E. L., Shaddix S. C., Brockman R. W., Bennett L. L. Comparisons of the actions of 9-β-D-arabinofur-anosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. 1982; 42: 2260–2264
   PubMed Web of Science ®Google Scholar
• Tseng W. C., Derse D., Cheng Y. C., Brockman R. W., Bennett L. L. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. 1982; 21: 474–477
   PubMed Web of Science ®Google Scholar
• Parker W. B., Bapat A. R., Shen J. X., Townsend A. J., Cheng Y. C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol 1988; 34: 485–491
   PubMed Web of Science ®Google Scholar
• Huang P., Chubb S., Plunkett W. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into DNA and its chain termination effect on DNA synthesis. J. Biol. Chem. 1990; 265: 16617–16625
   PubMed Web of Science ®Google Scholar
• Krenitsky T. A., Tuttle J. V., Koszalka G. W., Chen I. S., Beacham L. M., Rideout J. L., Elion G. B. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J. Biol. Chem. 1976; 251: 4055–4061
   PubMed Web of Science ®Google Scholar
• Avramis V. I., Champagne J., Sato J., Krailo M., Ettinga L. J., Poplack D. G., Finklestein J., Reaman G., Hammond G. D., Holcenberg J. S. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res. 1990; 50: 7226–7231
   PubMed Web of Science ®Google Scholar
• Heinemann V., Estey E. H., Keating M. J., Plunkett W. Patient-specific dose rate for continuous infusion high-dose arabinosylcytosine in relapsed acute myelogenous leukemia. J. Clin. Oncol 1989; 7: 622–628
   PubMed Web of Science ®Google Scholar
• Iacoboni S. J., Plunkett W., Kantarjian H. M., Estey E., Keating M. J., McCredie K. B., Freireich E. J. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J. Clin. Oncol 1986; 4: 1079–1088
   PubMed Web of Science ®Google Scholar
• Spriggs D. R., Stopa E., Mayer R. J., Schoene W., Kufe D. W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuro-pathological study. Cancer Res. 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Redman J., Cabanillas F., Velasquez W., McLaughlin P., Hagemeister F., Swan F., Rodriguez M., Plunkett W. K., Keating M. J. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low grade lymphoma. J. Clin. Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Hall R., Keating M. J., Estey E., Kantarjian H., McLaughlin P., Hagemeister F., Plunkett W. High-dose ara-C in chronic lymphocytic leukemia: A clinical and pharmacologic analysis. Leukemia Lymphoma, (in press)
   Google Scholar
• Andreeff M. Cell kinetics of leukemia. Sem. Hematol. 1986; 23: 300–314
   PubMed Web of Science ®Google Scholar
• Spriggs D., Robbins G., Mitchell T., Kufe D. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem. Pharmacol 1986; 35: 247–252
   PubMed Web of Science ®Google Scholar
• Huang P., Plunkett W. Actions of 9-0-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol. Pharmacol 1991; 39: 449–455
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-β-D-arabinosyl-2-fluoradenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Brager P. M., Grever M. R. 9-β-D-arabinofur-anosyl-2-fiuoroadenine (2-F-ara-A) reduces NAD in normal lymphocytes and neoplastic cells in CLL [Abstract]. Proc. Am. Assoc. Cancer Res. 1986; 27: 21
   Google Scholar
• Seto S., Carrera C. J., Kubots M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2'-chlorode-oxyadenosine toxicity to non-dividing human lymphocytes. J. Clin. Invest. 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Boldt D. H., Von Hoff D. D., Kuhn J. G., Hersh M. Effects on human peripheral lymphocytes of in vivo administration of 9-β-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. 1984; 44: 4661–4666
   PubMed Web of Science ®Google Scholar
• Feldmann M. Lymphocyte interactions and their mediators. The Lymphocyte, Structure and Function, J. J. Marchalonis. Marcel Dekker, Inc., New York 1988; 121–142
   Google Scholar